Complete Filing Data
XORTX Therapeutics Inc. reported Cash And Cash Equivalents of $864.5 thousand for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean XORTX Therapeutics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Research And Development Expense | $574.9K | $183.8K | $2.4M | $6.8M | $677.6K | $277.5K | $39.9K |
| Profit Loss Before Tax | -$3.3M | -$4.1M | -$6.0M | -$10.3M | -$2.9M | -$1.4M | -$566.0K |
| Profit Loss | -$2.7M | -$3.3M | -$2.2M | -$7.7M | -$1.6M | -$1.3M | -$629.6K |
| General And Administrative Expense | $241.0K | $320.9K | $375.5K | $448.8K | $140.0K | $9.5K | $17.3K |
| Comprehensive Income | -$2.7M | -$3.3M | -$2.2M | -$7.8M | -$1.4M | ||
| Amortization Of Intangible Assets And Goodwill | $26.4K | $31.1K | $66.6K | $17.1K | $14.3K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $864.5K | $2.5M | $3.4M | $10.4M | $14.9M | $134.5K | $58.6K | $260.0K |
| Purchase Of Intangible Assets Classified As Investing Activities | $55.2K | $38.9K | $42.1K | $26.0K | $31.8K | $14.4K | $7.0K | |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | $235.9K | -$134.4K | -$1.2M | $892.3K | -$259.3K | $405.2K | $353.3K | |
| Cash Flows From Used In Operating Activities | -$2.8M | -$3.7M | -$6.6M | -$8.2M | -$4.8M | -$728.4K | -$249.6K | |
| Cash Flows From Used In Financing Activities | $1.4M | $2.8M | -$361.0K | $3.9M | $19.4M | $855.4K | $55.2K | |
| Adjustments For Increase Decrease In Other Operating Payables | $162.8K | $208.2K | $142.7K | $622.6K | -$794.7K | -$43.0K | ||
| Adjustments For Decrease Increase In Trade Account Receivable | -$62.5K | $43.1K | $21.0K | -$41.1K | -$29.4K | $14.8K | ||
| Increase Decrease Through Exercise Of Warrants Equity | $14.00 | $3.00 | $296.00 | $64.00 | $2.3M | |||
| Cash Flows From Used In Investing Activities | -$295.0K | -$38.9K | -$46.4K | -$45.7K | -$31.8K | -$14.4K | ||
| Trade And Other Payables To Trade Suppliers | $553.8K | $147.2K | $283.4K | $1.4M | $552.9K | $1.0M | ||
| Retained Earnings | -$23.8M | -$21.2M | -$17.9M | -$15.7M | -$8.0M | -$8.0M | ||
| Liabilities | $599.1K | $758.0K | $825.9K | $5.4M | $4.2M | $1.0M | ||
| Intangible Assets And Goodwill | $185.4K | $183.1K | $175.3K | $199.8K | $202.1K | $234.3K | ||
| Equity Attributable To Owners Of Parent | $2.1M | $3.3M | $4.6M | $7.0M | $13.2M | $1.3M | ||
| Equity And Liabilities | $2.7M | $4.1M | $5.5M | $12.4M | $17.4M | $2.3M | ||
| Current Trade Receivables | $80.2K | $17.6K | $60.7K | $81.8K | $40.7K | $14.4K | ||
| Current Assets | $1.3M | $2.7M | $4.1M | $10.9M | $15.9M | $2.1M | ||
| Assets | $2.7M | $4.1M | $5.5M | $12.4M | $17.4M | $2.3M | ||
| Transaction Cost On Derivative Warrant Liability | -$279.0K | -$926.5K | -$1.3M | |||||
| Reclassification Of Derivative Warrant Liability | $123.7K | -$318.0K | -$3.5M | |||||
| Current Liabilities | $294.9K | $1.5M | $552.9K | $1.0M | ||||
| Current Lease Liabilities | $37.3K | $38.8K | $11.5K | $66.1K | ||||
| Accumulated Other Comprehensive Income | -$52.6K | -$52.6K | -$52.6K | -$52.6K | $75.5K | |||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $4.3K | $19.7K | ||||||
| Noncurrent Derivative Financial Liabilities | $531.0K | $3.9M | $3.6M | |||||
| Increase Decrease Through Issuance Of Warrants Equity | $741.8K | $908.0K | $925.0K | |||||
| Derivative Warrant Liability Reclassified To Share Capital On Exercise Of Warrants | $5.2K | $338.7K | ||||||
| Property Plant And Equipment Including Rightofuse Assets | $37.1K | $34.7K | $23.9K | |||||
| Current Derivative Financial Liabilities | $8.0K | $572.0K | $531.0K | |||||
| Transaction Costs On Derivative Warrant Liability | -$279.0K | -$797.6K | ||||||
| Recognition Of Derivative Warrant Liabilities | $10.1M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents | -$1.6M | -$974.0K | -$7.0M | -$4.4M | $14.7M | $112.7K | -$201.4K |
| Payments For Share Issue Costs | $738.4K | $667.9K | $295.3K | $1.1M | $698.6K | $44.6K | |
| Proceeds From Exercise Of Warrants | $14.00 | $16.6K | $296.00 | $64.00 | $1.9M | ||
| Proceeds From Issue Of Ordinary Shares | 2.3M | 3.5M | 5.0M | 18.1M | 900.0K | ||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $27.0K | -$36.0K | $4.0K | -$136.1K | $195.9K | ||
| Payments Of Lease Liabilities Classified As Financing Activities | $89.6K | $69.7K | $66.1K | $20.4K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Shares | 4.7M | 2.9M | 2.0M | 1.5M | 1.1M | 6.7M |
| Diluted Earnings Loss Per Share | $-0.56 | $-1.15 | $-1.09 | $-5.22 | $-1.44 | $-0.19 |
| Basic Earnings Loss Per Share | $-0.56 | $-1.15 | $-1.09 | $-5.22 | $-1.44 | $-0.19 |
| Adjusted Weighted Average Shares | 4.7M | 2.9M | 2.0M | 1.5M | 1.1M | 6.7M |
| Shares Issued Pursuant To Private Placements | 1.4M | 1.4M | 493.5K | 573.9K | 2.5M | |
| Shares Issued For Services | -59.1K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Travel Expense | $21.1K | $31.9K | $170.2K | $22.5K | $1.8K | $8.5K | $36.1K |
| Professional Fees Expense | $349.3K | $616.9K | $514.3K | $454.1K | $226.4K | $162.6K | $108.4K |
| Investor Relations | $595.8K | $1.4M | $919.5K | $928.4K | $412.1K | $241.2K | $34.8K |
| Interest And Other Expenses | $41.9K | $121.9K | $253.5K | $103.6K | -$4.5K | -$12.7K | -$35.6K |
| Increase Decrease Through Sharebased Payment Transactions | $25.2K | $122.5K | $121.0K | $487.9K | $396.4K | $293.4K | $26.3K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$23.7K | $34.2K | -$13.6K | -$6.4K | $28.3K | $1.2K | $34.1K |
| Adjustments For Sharebased Payments | $25.2K | $122.5K | $121.0K | $487.9K | $396.4K | $293.4K | $26.3K |
| Adjustments For Depreciation And Amortisation Expense | $112.1K | $117.3K | $139.7K | $58.1K | $14.3K | $20.4K | $19.9K |
| Foreign Exchange Gain Loss | -$73.0K | -$7.0K | -$1.5K | -$12.4K | $3.0K | -$26.4K | |
| Fair Value Of Expected Credit Loss | $564.0K | $1.0M | $3.6M | $3.4M | $2.6M | ||
| Directors Fees | $215.6K | $168.1K | $179.4K | $122.6K | $49.4K | ||
| Share Issuance Costs1 | $851.7K | $555.7K | $131.6K | $698.6K | $59.4K | ||
| Issued Capital | $20.2M | $18.5M | $17.1M | $16.5M | $16.1M | $8.3M | |
| Obligation To Issue Shares One | 24.7K | 24.7K | 24.7K | 24.7K | 32.2K | ||
| Contract Payments Non Current | $1.2M | $1.2M | $1.2M | $1.2M | $1.3M | ||
| Sharebased Payments | $121.0K | $487.9K | $396.4K | $293.4K | $26.3K | ||
| Public Company Costs | $120.3K | $141.4K | $170.2K | $120.8K | $188.6K | ||
| Prepaid Expenses | $185.4K | $237.0K | $379.6K | $1.0M | $264.2K | ||
| Consulting Wages And Benefits | $1.0M | $1.1M | $1.0M | $885.5K | $804.0K | ||
| Amortization Of Property And Equipment | $85.7K | $86.2K | $73.1K | $41.1K | |||
| Other Reserves | $5.8M | $6.0M | $5.5M | $6.2M | $5.0M | ||
| Wages And Benefits | $841.8K | $286.1K | $227.9K | $194.2K | |||
| Recognition Of Right Of Use Asset | $88.1K | $97.0K | $114.6K | ||||
| Fee And Commission Expense | $157.2K | $236.8K | $52.1K | $42.5K | |||
| Expense From Sharebased Payment Transactions With Employees | $25.2K | $122.5K | $121.0K | $487.9K | |||
| Depreciation And Amortisation Expense | $75.3K | $17.9K | $20.4K | $19.9K | |||
| Consulting | $309.2K | $724.3K | $102.9K | $46.6K | |||
| Reserve Of Sharebased Payments | $8.0M | $6.4M | $1.0M | ||||
| Fair Value Of Agents Warrants | $38.5K | $185.7K | |||||
| Share Issue Related Cost | $59.1K |
Most recent annual filing with the SEC: March 20, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.